The drugmaker plans to enroll 60 people in the study, all of whom previously got both doses of the original vaccine. The volunteers will receive either the new vaccine designed to combat the virus variant first found in South Africa, called B.1.351, or a single shot that contains both the variant vaccine and original vaccine, according to the Journal.
Moderna will also test if giving volunteers a third dose of the original vaccine can protect against the variants. If data from the trial is positive, the drugmaker could seek regulatory approval in the third quarter, the Journal reported.
The National Institutes of Health is also planning to study Moderna’s variant vaccine in people who didn’t get the original vaccine, The Hill reported.
More articles on pharmacy:
US will purchase 100M more J&J vaccines
Very few severe allergic reactions tied to mRNA vaccines, research shows
Pfizer’s newest vaccine manufacturing site has history of mold, recall troubles
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.